- Page 2/6
Signal
Opinion
Expert
HOLD
HOLD
BUY
BUY
January 13, 2021
Creating a huge base since last year. Has moved since vaccine announcements. Bumpy ride ahead. Two years forward, it will continue to recover as business activity normalizes. For the higher octane part of your portfolio. Be patient, and it should do well.
Show full opinionHide full opinion
Creating a huge base since last year. Has moved since vaccine announcements. Bumpy ride ahead. Two years forward, it will continue to recover as business activity normalizes. For the higher octane part of your portfolio. Be patient, and it should do well.
PAST TOP PICK
PAST TOP PICK
January 13, 2021
(A Top Pick Jan 30/20, Up 18%) Continues to buy. Growth from emerging markets over the next 10 years is quite strong. Normalization of activity will bring revenue to pre-pandemic levels by 2022. Diversified.
Show full opinionHide full opinion(A Top Pick Jan 30/20, Up 18%) Continues to buy. Growth from emerging markets over the next 10 years is quite strong. Normalization of activity will bring revenue to pre-pandemic levels by 2022. Diversified.
PAST TOP PICK
PAST TOP PICK
January 13, 2021
(A Top Pick Jan 30/20, Down 1%) Still likes. Continues to buy. Discount to other big pharma. Cancer drugs are very high margin. Pandemic has spurred pharma sales. Will benefit as life returns to normal. Yield is 3.1%.
Show full opinionHide full opinion(A Top Pick Jan 30/20, Down 1%) Still likes. Continues to buy. Discount to other big pharma. Cancer drugs are very high margin. Pandemic has spurred pharma sales. Will benefit as life returns to normal. Yield is 3.1%.
PAST TOP PICK
PAST TOP PICK
January 13, 2021
(A Top Pick Jan 30/20, Up 20%) Revenue has responded well to pandemic. Digital initiatives acting very well. Pay a premium at 36x forward earnings for 15% growth. Strong, iconic name. Cautious on buying going forward, based on valuation.
Show full opinionHide full opinion(A Top Pick Jan 30/20, Up 20%) Revenue has responded well to pandemic. Digital initiatives acting very well. Pay a premium at 36x forward earnings for 15% growth. Strong, iconic name. Cautious on buying going forward, based on valuation.
BUY
BUY
January 13, 2021
One of his top holdings. Not expensive. 24x earnings for 20-25% growth. Will benefit from long-term secular trend of more digital ads. Regulatory risks won't have a meaningful impact on earnings. If he had to choose between this and Google, he'd choose FB by a hair.
BUY
BUY
January 13, 2021
Revenue growth will continue to be strong. Will benefit from more and more digital advertising. If he had to choose this or Facebook, he'd choose FB, but it's close.
Revenue growth will continue to be strong. Will benefit from more and more digital advertising. If he had to choose this or Facebook, he'd choose FB, but it's close.
He holds Costco instead, as it brings in 3x as much in sales. WMT is a good name, but has lower growth prospects. Trying to enhance their digital experience, and he can't predict results just yet. 26x earnings, 6% earnings growth. Not cheap, but not expensive.